Metastasis is a dynamic succession of events involving the dissemination of tumour cells to
distant sites within the body, ultimately reducing the survival of patients with cancer. To …

The melanoma field has seen an unprecedented set of clinical advances over the past
decade. Therapeutic efficacy for advanced or metastatic melanoma went from being one of …

Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …

Cancer cells, including melanoma cells, often metastasize regionally through the lymphatic
system before metastasizing systemically through the blood–; however, the reason for this is …

For many solid malignancies, lymph node (LN) involvement represents a harbinger of
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …

Background In the previously reported primary analysis of this phase 3 trial, 12 months of
adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than …

The European annual incidence of malignant melanoma varies from 3–5/100 000 in
Mediterranean countries to 12–35/100 000 in Nordic countries, whereas it can reach over …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …

Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …